– Presentation will include safety and efficacy data from 21 patients treated in dose-escalation phase and early data from patients treated in dose-expansion phase –
– Additional poster exploring the significance of MRD negativity in patients in this study to be presented –
– Company to host conference call and live webcast,
“Since we first presented data for bb2121 in heavily pretreated patients
with multiple myeloma, we have been hopeful about its potential to
markedly improve the outcomes and expectations for this incurable
disease,” said
Oral Presentation
bb2121
anti-BCMA CAR T-cell therapy in patients with relapsed/refractory
multiple myeloma: Updated results from a multicenter phase I study.
(Abstract 8007)
Presenter:
Date & Time:
Location: E450
Session
Title: Hematologic Malignancies—Plasma Cell Dyscrasia
Poster Presentation
Early
MRD negativity to predict deepening myeloma response in
relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121
anti-BCMA CAR T cells. (Abstract 8024)
Presenter:
Poster Session Date & Time:
Location:
Poster Area Hall A
Session Title: Hematologic
Malignancies—Plasma Cell Dyscrasia
Conference Call & Webcast Information
bluebird bio will host a conference call and live webcast at
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio's gene therapy clinical programs include Lenti-D™ for the treatment of cerebral adrenoleukodystrophy, and LentiGlobin™ for the treatment of transfusion-dependent β-thalassemia, also known as β-thalassemia major, and severe sickle cell disease. bluebird bio's oncology pipeline is built upon the company's leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio's lead oncology programs, bb2121 and bb21217, are anti-BCMA CAR T programs partnered with Celgene. bluebird bio also has discovery research programs utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company's pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Washington, Durham, North Carolina and Zug,
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s research and development plans and
potential for the bb2121 product candidate to treat relapsed/refractory
multiple myeloma. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to the risk that any one or more of our product
candidates, including our bb2121 product candidate, will not be
successfully developed, approved or commercialized. For a discussion of
other risks and uncertainties, and other important factors, any of which
could cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors” in
our most recent Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent filings
with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180516006340/en/
Source: bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
bluebird bio, Inc.
Investors:
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com
or
Media:
Stephanie
Fagan, 201-572-9581
sfagan@bluebirdbio.com